Lead Product(s) : Recombinant Protein-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Reliance Life Sciences has been granted authorization to undertake a phase 1 clinical study of its recombinant protein-based Covid-19 vaccine candidate by the Central Drugs Standard Control Organisation (CDSCOS)'s Expert Committee (SEC).
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Recombinant Protein-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Protein Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reliance Life Sciences Seeks Approval for Phase I trial of its Covid Vaccine Candidate
Details : The aim of phase I clinical trials is to obtain reliable information on safety, tolerability, pharmacokinetics (PK), and mechanism of action of the recombinant protein based covid-19 vaccine with the objective of determining the maximum tolerated dose (M...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Recombinant Protein Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable